Entropy Neurodynamics (ASX:ENP) secured human research ethics committee approval for a phase 1b/2a study to evaluate TRP-8803 across eight major disorders under a single clinical framework, according to a Tuesday filing with the Australian bourse.

Indications for the basket study in 72 patients include anorexia nervosa, body dysmorphic disorder, obsessive-compulsive disorder, generalized anxiety disorder, post-traumatic stress disorder, treatment-resistant depression, fibromyalgia, and irritable bowel syndrome.

The company entered into a clinical trial research agreement with Swinburne University to support the study. Patient recruitment is due to start shortly across all indications, with first patient dosing expected later in the current quarter and dosing in initial cohorts anticipated before the end of the year.

The indications were selected based on the "growing clinical evidence" supporting the therapeutic potential of TRP-8803, which is Entropy's proprietary intravenously administered psilocin formulation.

The company's shares gained 3% in recent Tuesday trade.